^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF inhibitor

    Related drugs:
    3d
    Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=117, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Yidafan (ivonescimab)
    4d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer (clinicaltrials.gov)
    P2/3, N=840, Not yet recruiting, Pfizer
    New P2/3 trial
    |
    Opdivo (nivolumab)
    4d
    ctDNA-guided Treatment Decision-making (clinicaltrials.gov)
    P2, N=122, Recruiting, Fudan University
    New P2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Yidafan (ivonescimab)
    8d
    A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (clinicaltrials.gov)
    P1, N=328, Recruiting, HC Biopharma Inc.
    New P1 trial
    |
    EGFR mutation
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • etoposide IV
    10d
    A Randomized Controlled Trial on the Effectiveness and Safety of Ciliary Body Cryotherapy and Combined Anti-VEGF Therapy for Advanced Neovascular Glaucoma (ChiCTR2600117454)
    P=N/A, N=60, Not yet recruiting, Shanghai First People's Hospital; Shanghai First People's Hospital
    New trial
    10d
    Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma (ChiCTR2600117410)
    P=N/A, N=20, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
    New trial
    |
    Yidafan (ivonescimab)
    10d
    The occurrence and progression pattern of subretinal macular fibrosis in Chinese patients with wet AMD after anti-VEGF treatment: A prospective cohort study based on multi-omics - multimodal imaging linkage analysis of biological samples (ChiCTR2500113218)
    P=N/A, N=192, Not yet recruiting, Zhongshan Ophthalmic Center, Sun Yat-sen University; Zhongshan Ophthalmic Center, Sun Yat-sen University
    New trial
    10d
    Ivonescimab combined with chemotherapy treated with recurrent/persistent ovarian, fallopian tube, or primary peritoneal clear cell carcinoma patients：a single arm, open-label , single center exploratory study (ChiCTR2600115984)
    P=N/A, N=20, Not yet recruiting, West China Second Hospital of Sichuan University; West China Second Hospital of Sichuan University
    New trial
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Yidafan (ivonescimab)
    10d
    Safety,efficacy and mechanisms of envolimab and S-1 systemic therapy combined with intraperitoneal endostar in the treatment of gastric/gastric-oesophageal junction adenocarcinoma with malignant ascites in elderly patients over 70 years. (ChiCTR2500115706)
    P=N/A, N=30, Recruiting, Beijing Hospital; Beijing Hospital
    New trial
    |
    Teysuno (gimeracil/oteracil/tegafur) • Endostar (recombinant human endostatin)
    10d
    Prospective, Single-Center, Single-Arm Clinical Study of Ivosidenib (AK112) Combined with Chemotherapy for Neoadjuvant Treatment of Locally Advanced Oral Squamous Cell Carcinoma (ChiCTR2600117076)
    P4, N=15, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
    New P4 trial
    |
    carboplatin • paclitaxel • docetaxel • pemetrexed • Tibsovo (ivosidenib) • Yidafan (ivonescimab)
    10d
    AK112 (Ivosimlimab) in combination with chemotherapy as first-line treatment for recurrent or advanced endometrial cancer (ChiCTR2500111544)
    P4, N=50, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P4 trial
    |
    Yidafan (ivonescimab)
    10d
    A Single-Arm, Multicenter Clinical Study of Eribulin Mesylate in Combination with Ivonescimab as First-Line Treatment for Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ChiCTR2600117652)
    P2, N=50, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Halaven (eribulin mesylate) • Yidafan (ivonescimab)